Trial Profile
Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 22 Nov 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Oct 2019 Planned initiation date changed from 1 Sep 2019 to 1 Dec 2019.
- 18 Jul 2019 Planned initiation date changed from 1 Jun 2019 to 1 Sep 2019.